Status Migrenozus
Özet
Status migrenozus, 72 saatten uzun süren, auralı veya aurasız migrenin şiddetli bir komplikasyonudur. Tanısı ICHD-3 kriterlerine dayanır ve altta yatan patofizyolojisinde trigeminovasküler sistem ile kalsitonin geni ile ilişkili peptit (CGRP) gibi nörolojik faktörler rol oynar. Tedavi yaklaşımı; antidopaminerjikler, triptanlar, NSAID'ler ve IV sıvı replasmanı gibi kombinasyon terapilerini içerirken, dirençli vakalarda ketamin, propofol veya lidokain gibi ileri seçenekler değerlendirilebilir. Eğitim ve tetikleyicilerin yönetimi, bu durumun önlenmesinde kritik rol oynar.
Status migrenosus is a severe complication of migraine defined as an attack lasting more than 72 hours. Diagnosis is based on ICHD-3 criteria, and its pathophysiology involves neurological factors such as the trigeminovascular system and calcitonin gene-related peptide (CGRP). Treatment strategies include combination therapies like antidopaminergics, triptans, NSAIDs, and IV fluid resuscitation, while refractory cases may require advanced options such as ketamine, propofol, or lidocaine. Effective prevention relies on patient education and the management of individual triggers.
Referanslar
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1.
The International Classification of Headache Disorders: 2nd edition. Headache Classification Subcommittee of the International Headache Society Cephalalgia. 2004;24 Suppl 1:9.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
Abigail L. Chua, DO; Brian M. Grosberg, MD; Randolph W. Evans, MD. Status Migrainosus in Children and Adults. Headache 2019;59:1611-1623.
The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629–808
Tarun D Singh, F Michael Cutrer Jonathan H Smith. Episodic status migrainosus: A novel migraine subtype Cephalalgia 2018, Vol. 38(2) 304–311.
Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065. Epub 2010 Mar 12.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis. Cephalalgia.2014;34:633-637.
Pryse-Phillips W, Aube M, Bailey P, et al. A clinical study of migraine evolution. Headache. 2006;46:1480-1486.
Ducros A, Tournier-Lasserve E, Bousser MG. The genetics of migraine. Lancet Neurol 2002; 1:285.
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658.
Leão AA. Pial circulation and spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7:391.
Martignoni E, Solomon S. The complex chronic headache, mixed headache, and drug overuse. In: The Headaches, Olesen J, Tfelt-Hansen P, Welch KM (Eds), Raven, New York 1993. p.849
Qubty W, Patniyot I Migraine Pathophysiology. Pediatr Neurol. 2020;107:1. Epub 2020 Feb 4.
Ashina M. Migraine. N Engl J Med. 2020;383(19):1866.
Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8:136.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: An 11-year retrospective analysis. Cephalalgia. 2014;34:633-637.
Akhtar ND, Murray MA, Rothner AD. Status migrainosus in children and adolescents. Semin Pediatr Neurol. 2001;8:27-33.
Negro A, Rocchietti-March M, Fiorillo M, Martelletti P. Chronic migraine: Current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci. 2011;15:1401-1420.
Whyte C, Tepper SJ, Evans RW. Expert opinion: Rescue me: Rescue medication for migraine.Headache. 2010;50:307-313.
Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: Potential for a larger role. Headache. 2006;46(Suppl. 4):S212-S220.
Swaiman KF: Headache in Children and Adolescents In:Swaıman KF, Ashwal S, Ferrıero DM(eds). Pediatric Neurology Principles&Practice,Philadephia:Elsevier Inc, 2017: 647-655.
Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43:521-546.)
Sheridan DC, Spiro DM, Nguyen T, Koch TK, Meckler GD. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012;28:1293-1296.)
Ayulo MA Jr, Phillips KE, Tripathi S. Safety and efficacy of IV lidocaine in the treatment of children and adolescents with status migraine. Pediatr Crit Care Med. 2018;19:755-759.)
Zafar MS, Stewart AM, Toupin DN, Cook AM, Baumann RJ. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. Neurologist. 2018;23:43-46.
Szperka CL, Gelfand AA, Hershey AD. Patterns of use of peripheral nerve blocks and trigger point injections for pediatric headache: Results of a survey of the American Headache Society Pediatric and Adolescent Section. Headache. 2016;56:1597-1607
Nović A, Kolves K, O'Dwyer S, De Leo D. Migraine and suicidal behaviors: A systematic literature review. Clin J Pain. 2016;32:351-364
